Johnson & Johnson insider trading
JNJfinancial statementsForm 4 filings on EDGAR250 transactions since Nov 1, 2024
From August 4, 2026 to November 1, 2026, 0 insiders at Johnson & Johnson bought $0 of stock in the open market, and 4 sold $62M. Officers and directors accounted for $0 of purchases and $62M of sales. The last reported transaction was an option exercise by Schmid Timothy on September 2, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through September 4, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $62MAug 4, 2026 – Nov 1, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Oct 30, 2026. Insider data through Nov 1, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
250 transactions from November 1, 2024 to November 1, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | option exercise | 11,070 | $131.94 | $1M | 36,517 | Sep 4, 2026 |
| Sep 2, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | open-market sale | 11,070 | $274.74 | $3M | 25,447 | Sep 4, 2026 |
| Sep 2, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | option exercise | 22,527 | $151.41 | $3M | 47,974 | Sep 4, 2026 |
| Sep 2, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | open-market sale | 22,527 | $274.74 | $6M | 25,447 | Sep 4, 2026 |
| Aug 17, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | option exercise | 15,000 | $115.67 | $2M | 209,451 | Aug 18, 2026 |
| Aug 17, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | open-market sale | 15,000 | $263.36 | $4M | 194,451 | Aug 18, 2026 |
| Aug 13, 2026 | Duato Joaquin | CEO and Chairman of the Board, Director | option exercise | 123,291 | $115.67 | $14M | 399,258 | Aug 14, 2026 |
| Aug 13, 2026 | Duato Joaquin | CEO and Chairman of the Board, Director | open-market sale | 20,976 | $262.00 | $5M | 378,282 | Aug 14, 2026 |
| Aug 13, 2026 | Duato Joaquin | CEO and Chairman of the Board, Director | open-market sale | 102,315 | $261.00 | $27M | 275,967 | Aug 14, 2026 |
| Aug 6, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | option exercise | 9,344 | $131.94 | $1M | 32,912 | Aug 7, 2026 |
| Aug 6, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | open-market sale | 9,344 | $257.75 | $2M | 23,568 | Aug 7, 2026 |
| Aug 6, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | open-market sale | 6,574 | $255.93 | $2M | 16,994 | Aug 7, 2026 |
| Aug 5, 2026 | Duato Joaquin | CEO and Chairman of the Board, Director | open-market sale | 41,957 | $258.06 | $11M | 282,490 | Aug 7, 2026 |
| Aug 5, 2026 | Duato Joaquin | CEO and Chairman of the Board, Director | open-market sale | 6,523 | $258.74 | $2M | 275,967 | Aug 7, 2026 |
| Jul 20, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | option exercise | 11,129 | $129.51 | $1M | 34,132 | Jul 21, 2026 |
| Jul 20, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | option exercise | 11,925 | $131.94 | $2M | 46,057 | Jul 21, 2026 |
| Jul 20, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | open-market sale | 23,054 | $251.27 | $6M | 23,003 | Jul 21, 2026 |
| Jun 11, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | option exercise | 10,000 | $115.67 | $1M | 124,288 | Jun 12, 2026 |
| Jun 11, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | open-market sale | 10,000 | $241.15 | $2M | 114,288 | Jun 12, 2026 |
| May 1, 2026 | Reed John C | EVP, Innovative Medicine, R&D | option exercise | 25,255 | $0.00 | — | 35,913 | May 4, 2026 |
| May 1, 2026 | Reed John C | EVP, Innovative Medicine, R&D | tax withholding | 11,002 | $229.85 | $3M | 24,911 | May 4, 2026 |
| Feb 27, 2026 | Decker Robert J | VP Corporate Controller | open-market sale | 4,075 | $247.87 | $1M | 23,682 | Mar 3, 2026 |
| Feb 27, 2026 | Decker Robert J | VP Corporate Controller | option exercise | 4,075 | $115.67 | $471K | 27,757 | Mar 3, 2026 |
| Feb 20, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | open-market sale | 1,322 | $245.66 | $325K | 25,447 | Feb 23, 2026 |
| Feb 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | open-market sale | 8,998 | $244.53 | $2M | 26,769 | Feb 18, 2026 |
| Feb 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | option exercise | 8,998 | $129.51 | $1M | 35,767 | Feb 18, 2026 |
| Feb 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | open-market sale | 13,625 | $244.20 | $3M | 26,769 | Feb 18, 2026 |
| Feb 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | option exercise | 13,625 | $115.67 | $2M | 40,394 | Feb 18, 2026 |
| Feb 17, 2026 | Swanson James D. | EVP, CIO | open-market sale | 20,521 | $242.70 | $5M | 25,698 | Feb 18, 2026 |
| Feb 17, 2026 | Swanson James D. | EVP, CIO | option exercise | 20,521 | $164.62 | $3M | 46,219 | Feb 18, 2026 |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | option exercise | 12,066 | $129.51 | $2M | 51,027 | Feb 18, 2026 |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | option exercise | 19,241 | $115.67 | $2M | 58,202 | Feb 18, 2026 |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | open-market sale | 19,241 | $242.99 | $5M | 38,961 | Feb 18, 2026 |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | open-market sale | 24,961 | $242.68 | $6M | 14,000 | Feb 18, 2026 |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | open-market sale | 33,386 | $242.75 | $8M | 38,961 | Feb 18, 2026 |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | option exercise | 33,386 | $131.94 | $4M | 72,347 | Feb 18, 2026 |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | open-market sale | 12,066 | $242.87 | $3M | 38,961 | Feb 18, 2026 |
| Feb 17, 2026 | Reed John C | EVP, Innovative Medicine, R&D | option exercise | 29,927 | $156.15 | $5M | 42,868 | Feb 18, 2026 |
| Feb 17, 2026 | Reed John C | EVP, Innovative Medicine, R&D | open-market sale | 29,927 | $243.00 | $7M | 12,941 | Feb 18, 2026 |
| Feb 17, 2026 | Reed John C | EVP, Innovative Medicine, R&D | open-market sale | 2,283 | $243.00 | $555K | 10,658 | Feb 18, 2026 |
| Feb 17, 2026 | Reed John C | EVP, Innovative Medicine, R&D | open-market sale | 21,721 | $243.00 | $5M | 12,941 | Feb 18, 2026 |
| Feb 17, 2026 | Reed John C | EVP, Innovative Medicine, R&D | option exercise | 21,721 | $157.92 | $3M | 34,662 | Feb 18, 2026 |
| Feb 17, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | open-market sale | 6,197 | $243.39 | $2M | 23,003 | Feb 18, 2026 |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | tax withholding | 309 | $243.45 | $75K | 25,698 | Feb 18, 2026 |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | option exercise | 709 | $0.00 | — | 26,007 | Feb 18, 2026 |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | tax withholding | 214 | $243.45 | $52K | 25,298 | Feb 18, 2026 |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | option exercise | 492 | $0.00 | — | 25,512 | Feb 18, 2026 |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | option exercise | 606 | $0.00 | — | 114,288 | Feb 18, 2026 |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | tax withholding | 310 | $243.45 | $75K | 113,978 | Feb 18, 2026 |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | option exercise | 635 | $0.00 | — | 114,613 | Feb 18, 2026 |
Who the insiders are
Everyone who reported a transaction since November 1, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Duato Joaquin | CEO and Chairman of the Board, Director | Aug 13, 2026 | option exercise | 399,258 | — | $67M (6) | 0 of 6 |
| Wolk Joseph J | Exec VP, CFO | Feb 17, 2026 | option exercise | 51,027 | — | $22M (4) | 0 of 4 |
| Swanson James D. | EVP, CIO | Feb 17, 2026 | open-market sale | 25,698 | — | $15M (3) | 0 of 3 |
| Schmid Timothy | EVP, WW Chair, MedTech | Sep 2, 2026 | option exercise | 36,517 | — | $15M (5) | 0 of 5 |
| Reed John C | EVP, Innovative Medicine, R&D | May 1, 2026 | option exercise | 35,913 | — | $13M (3) | 0 of 3 |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Jul 20, 2026 | option exercise | 34,132 | — | $7M (2) | 0 of 2 |
| Forminard Elizabeth | EVP, Chief Legal Officer | Aug 6, 2026 | option exercise | 32,912 | — | $4M (2) | 0 of 2 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | Aug 17, 2026 | option exercise | 209,451 | — | $4M (1) | 0 of 1 |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | Jun 11, 2026 | option exercise | 124,288 | — | $2M (1) | 0 of 1 |
| Decker Robert J | VP Corporate Controller | Feb 27, 2026 | open-market sale | 23,682 | — | $1M (1) | 0 of 1 |
| Morikis John G | Director | Nov 26, 2025 | open-market buy | 1,849 | $258K (1) | — | — |
| Mulholland Kristen | EVP, Chief HR Officer | Feb 15, 2026 | option exercise | 20,081 | — | — | — |
| Weinberger Mark A | Director | Dec 12, 2024 | open-market buy | 1,000 | — | — | — |
Questions
Are Johnson & Johnson insiders buying or selling?
Over the twelve months to November 1, 2026, 10 insiders at Johnson & Johnson sold $151M of stock in the open market, all by officers and directors, and 1 insider bought $258K, all by officers and directors. Net, insiders sold $150M. Only open-market purchases and sales are counted.
Who sold the most Johnson & Johnson stock in the last year?
Duato Joaquin (CEO and Chairman of the Board, Director) sold $67M in 6 open-market sales over the twelve months to November 1, 2026.
Do Johnson & Johnson executives sell under 10b5-1 plans?
0 of the 28 open-market sales in the last twelve months (0%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Johnson & Johnson
- Johnson & Johnson financial statements
- 1 tracked fund holding JNJ
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.